Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer

Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer (ESCC) patients who were previously treated with multiple systemic therapies. Between January 2016 and December 2018, records of 38 ESCC patients who underwent irinotecan plus raltitrexed chemotherapy after at least one line of chemotherapy were reviewed. Efficacy assessment was performed every two cycles according to the RECIST version 1.1. A total of 95 cycles of chemotherapy were administered, and the median course was 3 (range 2–6). There was no treatment-related death. Nine patients had partial response, 21 had stable disease and eight had progressive disease. The overall objective response rate was 23.68% (9/38) and the disease control rate was78.94% (30/38). After a median follow-up of 18.5 months, the median progression-free survival and overall survival were 105 and 221 days, respectively. There were five patients (13.15%) with grade 3/4 leukopenia, three patients (7.89%) with grade 3/4 neutropenia and one patient (2.63%) with grade 3/4 diarrhea. The combination of irinotecan plus raltitrexed was effective for pretreated ESCC patients. Further studies are needed to determine the optimal dose of the two drugs.

[1]  Ftlo Bonin-Cecelia,et al.  Phase II: , 2020, The Power of Accountability.

[2]  Ying Cheng,et al.  Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial , 2019, Cancer communications.

[3]  Xinchen Sun,et al.  Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells , 2019, Cancer Cell International.

[4]  T. Okuno,et al.  Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer , 2018, The oncologist.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  J. Lagergren,et al.  Smoking Cessation and Risk of Esophageal Cancer by Histological Type: Systematic Review and Meta-analysis , 2017, Journal of the National Cancer Institute.

[7]  Dong-Wan Kim,et al.  Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[8]  H. Nagano,et al.  Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer. , 2016, Anticancer research.

[9]  Jing Huang,et al.  Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma , 2015, Thoracic cancer.

[10]  W. Hong,et al.  Raltitrexed-based chemotherapy for advanced colorectal cancer. , 2014, Clinics and research in hepatology and gastroenterology.

[11]  N. Sugimoto,et al.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Harrison,et al.  Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. , 2013, European journal of cancer.

[13]  M. Cool,et al.  Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. , 2013, Clinical colorectal cancer.

[14]  J. Ajani,et al.  Weekly docetaxel, cisplatin, and 5‐fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer , 2010, Cancer.

[15]  Y. Shinomura,et al.  Phase I/II Study of Docetaxel/Cisplatin/Fluorouracil Combination Chemotherapy Against Metastatic Esophageal Squamous Cell Carcinoma , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  K. Wilson,et al.  Raltitrexed: optimism and reality , 2009, Expert opinion on drug metabolism & toxicology.

[17]  C. Bokemeyer,et al.  A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. , 2007, Anticancer research.

[18]  H. McLeod,et al.  Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks , 2007, Cancer Chemotherapy and Pharmacology.

[19]  J. Feliu,et al.  Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer , 2005, British Journal of Cancer.

[20]  J. Aparicio,et al.  First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer , 2005, Oncology.

[21]  R. Rosso,et al.  Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer. , 2005, Anticancer research.

[22]  V. Gebbia,et al.  Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. , 2004, Anticancer research.

[23]  L. Assersohn,et al.  Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  J. Aparicio,et al.  Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  W. Scheithauer,et al.  Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma , 2003, British Journal of Cancer.

[26]  A. Santoro,et al.  Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Harris,et al.  A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  W. Scheithauer,et al.  Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  S. Sirilerttrakul,et al.  Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy. , 2000, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[30]  J. Paul,et al.  A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma , 2000, British Journal of Cancer.

[31]  J. Bertino,et al.  Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.